Teva Pharmaceutical Industries (NYSE:TEVA) Earns Buy Rating from Analysts at The Goldman Sachs Group
The Goldman Sachs Group started coverage on shares of Teva Pharmaceutical Industries (NYSE:TEVA – Get Free Report) in a research note issued on Friday, MarketBeat reports. The firm set a “buy” rating and a $24.00 price target on the stock. The Goldman Sachs Group’s price target would indicate a potential upside of 35.14% from the […]
The Goldman Sachs Group started coverage on shares of Teva Pharmaceutical Industries (NYSE:TEVA – Get Free Report) in a research note issued on Friday, MarketBeat reports. The firm set a “buy” rating and a $24.00 price target on the stock. The Goldman Sachs Group’s price target would indicate a potential upside of 35.14% from the […]
